Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9T4 | ISIN: US8112922005 | Ticker-Symbol: 135A
Tradegate
28.03.25
21:25 Uhr
0,906 Euro
-0,023
-2,48 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCYNEXIS INC Chart 1 Jahr
5-Tage-Chart
SCYNEXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9200,96013:04
0,9060,95228.03.

Aktuelle News zur SCYNEXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.03.SCYNEXIS GAAP EPS of -$0.44 misses by $0.98, revenue of $3.75M misses by $63.25M1
12.03.SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update705The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted...
► Artikel lesen
SCYNEXIS Aktie jetzt für 0€ handeln
12.03.SCYNEXIS INC - 10-K, Annual Report1
18.12.24SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections194JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...
► Artikel lesen
07.11.24SCYNEXIS GAAP EPS of -$0.06, revenue of $0.66M1
06.11.24SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update147Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
06.11.24SCYNEXIS kündigt neuen Aktienverkaufsvertrag über 50 Millionen US-Dollar an12
06.11.24SCYNEXIS announces new $50 million equity sales agreement1
06.11.24SCYNEXIS INC - 8-K, Current Report-
06.11.24SCYNEXIS INC - 10-Q, Quarterly Report-
10.10.24SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit2
03.10.24SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 20242
08.08.24SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update220Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
23.07.24SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report388LONDON (dpa-AFX) - SCYNEXIS Inc. (SCYX) announced it will receive a $10 million development milestone payment from GSK under their license agreement for ibrexafungerp. The milestone payment...
► Artikel lesen
08.05.24SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update405SCY-247's IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory...
► Artikel lesen
30.04.24SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)202In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1